Global Immunoassay Market Strategies and Trends Report 2022

Dublin, November 25, 2021 (GLOBE NEWSWIRE) – The “Immunoassay Market: Strategies and Trends, Forecast by Application, Technology, Product, User and Country, with Multiplex and Point of Service Market Analysis, Executive Guides, Forecast and Custom Analysis – 2022 to 2026” the report was added to ResearchAndMarkets.com offer.

The workhorse of the diagnostics industry is finding new legs. The pandemic has created a new demand for quick and readily available diagnostics. The immunoassay is intensifying.

Advances in genetic knowledge are creating new markets for immunoassays. Rapid diagnostics, point-of-care, biomarkers, and consumer markets are all areas of expansion, while traditional immunoassays maintain a strong position in the growing clinical diagnostics market.

The editor profiles 58 companies, large and small, active in this field. This research makes you the expert in your organization.

All report data is available in Excel format upon request. Make investment decisions and valuations with confidence using the latest data.

Main topics covered:

1 Market Guides
1.1 Immunoassay Market – Strategic Analysis of the COVID Situation and Impact
1.2 Guide for Executives, Marketing, Sales and Business Development Personnel
1.3 Guide for management and investment advisers

2 Market introduction and definition
2.1 Definition of Immunoassay Markets in this Report
2.1.1 Enzyme-based
2.1.2 Immunofluorescence
2.1.3 Chemiluminescence
2.1.4 DNA / NAT
2.1.5 AIR and others
2.1.6 Reagents / Kits, Analyzers, Software & Services
2.1.7 Infectious disease
2.1.8 Autoimmune
2.1.9 Endocrinology
2.1.10 Oncology
2.1.11 Cardiology
2.1.12 Other specialty
2.2 Market definition
2.2.1 Market sizes
2.2.2 Currency
2.2.3 Years
2.3 Methodology
2.3.1 Authors
2.3.2 Sources
2.4 Perspective: Healthcare, IVD Industry and the COVID-19 Pandemic
2.4.1 Global health care expenditure
2.4.2 Diagnostic expenditure
2.4.3 Important role of insurance for diagnostics

3 Industry overview
3.1 Industry participants
3.1.1 IVD provider
3.1.2 Independent specialized / esoteric laboratory
3.1.3 National / regional independent laboratory
3.1.4 Independent analytical laboratory
3.1.5 Public National / regional laboratory
3.1.6 Hospital laboratory
3.1.7 Physician’s laboratory
3.1.8 Supervisory body
3.2 Clinical laboratory market segments
3.2.1 Traditional market segmentation
3.2.2 Laboratory concentration and segmentation
3.2.3 Share of hospital tests
3.2.4 Economies of scale
3.2.5 Hospital vs. Central laboratory
3.2.6 Physician’s office laboratory
3.2.7 Doctor and POCT
3.3 Immunoassay – Markets and discussion
3.3.1 Instruments – Genetics is a game-changer
3.3.1.1 RIA – A technology shows its age
3.3.1.2 Immunoassay vs. PCR vs. Sequencing – A roller coaster battle
3.3.1.3 The Smart Shrinkage Instrument – Serious Implications
3.3.1.4 Research funding and capital expenditure – Pooling of instruments
3.3.1.5 Multiplex vs POC – A compromise analysis
3.3.2 Reagents and kits – Genetics are a game-changer
3.3.2.1 Bigger test menus a godsend for the kit market
3.3.2.2 Doctor’s office laboratories – A new frontier
3.3.3 Rapid and POCT to threaten instrument markets
3.3.4 OTC and DTC – Huge Market Potential
3.3.5 Economies of scale. Leave?
3.3.6 Lower entry barriers for instruments / analyzers
3.3.7 Miniaturization and acquisition of technology

4 market trends
4.1 Growth factors
4.1.1 Diagnostic factors
4.1.2 Developments in technology encourage early retirement of instruments
4.1.3 Consumption channels are opening up more widely
4.1.4 Immunity technology matures
4.2 Factors limiting growth
4.2.1 Increased competition lowers the price
4.2.2 Threat of PCR-based instruments
4.2.3 Lower barriers to entry
4.2.4 Well-being has a downside
4.3 Immunoassay instrumentation
4.3.1 Instrumentation toughness
4.3.2 The fall in the cost of instruments is changing the structure of the industry
4.3.3 List of instrument specifications
4.3.4 Immunoassay – CRISPR Diagnostics

5 Recent developments in immunoassay
5.1 Recent Developments – Importance and Use of this Section
5.1.1 Significance of these changes
5.1.2 How to use this section
5.2 FDA grants EUA to Xtrava Health’s COVID point-of-care antigen test
5.3 Alamar Biosciences raises $ 80 million for an immuno-sandwich assay platform
5.4 FDA grants breakthrough device for multiplex immunoassay
5.5 Quidel and Beckman resolve dispute over cardiac immunoassay
5.6 BGI Americas, Advaite Form SARS-CoV-2 Testing Partnership
5.7 BioMérieux obtains CE marking for three immunological tests against dengue
5.8 COVID-19 portfolio to accelerate the detection of infectious diseases at home
5.9 Roche Diagnostics expands its test portfolio in 2021
5.10 Long-term outlook for PerkinElmer
5.11 Quidel updates Outlook for C19 tests
5.12 Dx Companies Review Multiplex Testing for SARS-CoV-2, Influenza
5.13 Acquisition of Becton Dickinson and NAT Diagnostics
5.14 New test diagnoses Lyme disease in 15 minutes
5.15 The multiplex immunoassay system differentiates malaria species
5.16 ERBA Mannheim Unveils Next Generation Nexus Unit
5.17 Uman Diagnostics and Bio-Techne Announce Agreement for Light Neurofilament Test
5.18 Software reduces variability in ELISA biomarker assays
5.19 Arrayit Corporation’s Allergy Testing Network Doubles

6 key company profiles
6.1 Abbott diagnostics
6.2 Abcam
6.3 Arlington Scientist
6.4 Arrayit Company
6.5 Autobio diagnostics
6.6 Awareness technology
6.7 Beckman Coulter Diagnosis
6.8 Becton, Dickinson and company
6.9 Biocartis
6.10 Biomatik
6.11 BioMérieux Diagnostics
6.12 Bioneer company
6.13 Bio-Rad Laboratories, Inc.
6.14 BioTek Instruments
6.15 Boditech Med, Inc
6.16 Boost biological technology
6.17 Diamedix (Erba diagnostic)
6.18 Diasorin SpA
6.19 Dynex Technologies
6.20 Enzo Biochem
6.21 Eurofins Scientific
6.22 FUJIFILM Wako Diagnostics
6.23 Fujirebio
6.24 Gold Standard Diagnosis
6.25 Grifol
6.26 Hycor Biomedical
6.27 Immunodiagnostic systems (IDS)
6.28 Immunodiagnostik AG
6.29 Inova diagnosis
6.30 JR Biomedical
6.31 Luminex Corp
6.32 Maxim Biomedical
6.33 Mbio Diagnosis
6.34 Discovery of the meso scale
6.35 Millipore Sigma
6.36 Mindray
6.37 Molecular devices
6.38 MP Biomedical
6.39 MyCartis
6.40 Operon
6.41 Orthoclinical diagnosis
6.42 Perkin Elmer
6.43 Qiagen GmbH
6.44 Quidelle
6.45 R&D systems
6.46 Randox Toxicology
6.47 Roche Molecular Diagnostics
6.48 SD Biosensor
6.49 Serametrix
6.50 Siemens Healthineers
6.51 Sysmex
6.52 Tecan
6.53 Thermo Fisher Scientific Inc.
6.54 TOSOH Biosciences
6.55 Veredus Laboratories
6.56 Vircell
6.57 YD Diagnostics
6.58 Zhejiang Orient Gene Biotech

7 The global market
7.1 Global Market by Country
7.2 Global Market by Application
7.3 Global Market by Technology
7.4 Global Market by Product
7.5 Global Market by User

8 Global Market by Application
8.1 Endocrinology applications
8.2 Immune applications
8.3 Applications in oncology
8.4 Applications in infectious diseases
8.5 Applications in cardiology
8.6 Other applications

9 Immunoassay by technology
9.1 Enzyme
9.2 Fluorescence
9.3 Chemiluminescence
9.4 Nucleic acid
9.5 Fast / POC
9.6 Other technology

10 Immunoassay per product
10.1 Instrumentation
10.2 Reagents
10.3 Services

11 User immunoassay
11.1 Hospital
11.2 Ambulatory laboratory
11.3 POC / Other

12 Vision for the future of immunoassay

13 Appendices
13.1 United States Medicare System: Laboratory Fee Schedule for 2021

For more information on this report, visit https://www.researchandmarkets.com/r/q5xqdx


        


Source link

Comments are closed.